ReviewDiscover nano2025
SERS-guided photodynamic therapy: pioneering strategies in advanced cancer diagnosis and treatment.
Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial Intelligence in Photodynamic Therapy: From Molecular Design of Photosensitizers to Intelligent Delivery, Adaptive Dosimetry, and Personalized Prognostication of Results.International journal of molecular sciences · 2026Review
- Harnessing Rare-Earth Materials as Exogenous Contrast Agents for Enhanced Photoacoustic Imaging.Chemical & biomedical imaging · 2026Review
- Label-Free SERS Analysis of Glioma Cells to Detect Drug Resistance Using Metabolic Phenylalanine Level.ACS measurement science au · 2026Article
- Review
- Design, Implementation, and Advances in Indirect SERS Sensors for Biomedical and Human-Health-Related Analyte Detection.Sensors (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of mortality worldwide, and while advances in conventional therapies such as chemotherapy, radiotherapy, and targeted therapies have improved patient outcomes, these treatments often fail to meet the demand for precision and specificity. Many current therapies struggle with limitations such as non-specific targeting, drug resistance, and significant side effects, often leading to incomplete tumor eradication and damage to surrounding healthy tissues. The urgent need for more precise, minimally invasive, and efficient cancer treatment strategies has paved the way for novel therapeutic approaches. Cancer theranostics has evolved exceptionally by incorporating new diagnostic tools that ultimately improve the therapeutic outcome of the treatment. Surface Enhanced Raman Spectroscopy (SERS)-guided photodynamic therapy (PDT) is rapidly gaining attention as a highly sophisticated modality in cancer theranostics, offering a dual advantage of enhanced diagnostic precision and effective therapeutic action. SERS, an ultra-sensitive molecular imaging technique, provides real-time, high-resolution detection of cancer biomarkers, enabling precise tumor localization and characterization. SERS-based theranostic probes can show potential results in both in-vivo and in-vitro studies. Herein this review critically discusses the key roles of SERS during the PDT treatment and also focuses on providing brief information on the fundamentals of both SERS and PDT. In combination with PDT, which selectively destroys cancer cells through photosensitizer activation under light exposure, SERS-guided PDT ensures a targeted therapeutic approach that minimizes damage to surrounding healthy tissues and reduces side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.